Previous 10 | Next 10 |
home / stock / hluyy / hluyy news
With the interim analysis of the Rexulti Alzheimer's agitation study leading to study continuation, Lundbeck's cupboard of near-term catalysts is looking pretty bare. A strong efficacy signal in the Phase II Rexulti study in borderline personality disorder or strong acceleration in Vy...
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
H Lundbeck A/S (HLUKF) Q1 2021 Earnings Conference Call May 11, 2021, 07:00 ET Company Participants Deborah Dunsire - President & CEO Anders Götzsche - EVP & CFO Johan Luthman - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial...
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2021 Q1 earnings call. For further details see: H. Lundbeck A/S 2021 Q1 - Results - Earnings Call Presentation
Lundbeck has posted some lackluster recent quarters, with the pandemic weighing heavily on results for a company where face-to-face doctor visits are important. The upcoming interim analysis of a Phase III study of Rexulti in Alzheimer's agitation is a key for the company, potentially...
H. Lundbeck A/S (HLUKF) Q4 2020 Earnings Conference Call February 04, 2021 07:00 AM ET Company Participants Deborah Dunsire - President & Chief Executive Officer Anders Götzsche - Executive Vice President & Chief Financial Officer Johan Luthman - Executive Vice President, Researc...
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q4 earnings call. For further details see: H. Lundbeck A/S 2020 Q4 - Results - Earnings Call Presentation
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q3 earnings call. For further details see: H. Lundbeck A/S 2020 Q3 - Results - Earnings Call Presentation
H Lundbeck A/S (HLUKF) Q3 2020 Earnings Conference Call November 03, 2020, 07:00 ET Company Participants Deborah Dunsire - President & CEO Johan Luthman - EVP of R&D Anders Götzsche - EVP & CFO Peter Anastasiou - EVP, North America Conference Call Participants Wimal Kapadia -...
Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...
News, Short Squeeze, Breakout and More Instantly...
H Lundbeck A/S S/Adr Company Name:
HLUYY Stock Symbol:
OTCMKTS Market:
Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
COPENHAGEN, Denmark , Aug. 31, 2020 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study [i] that assessed the efficacy and tolerability of Vyepti when initiated during a migrain...